Serina Therapeutics Inc. (NYSE American: SER), a clinical-stage biotechnology company, announced it has received the first $5 million tranche under a financing agreement totaling up to $20 million. The funding, provided solely to Serina Therapeutics, will support the planned registrational trial of SER-252, an investigational treatment for advanced Parkinson's disease. The company has also submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration and obtained Human Research Ethics Committee (HREC) approval in Australia. Serina remains on track to initiate its global clinical trial in the fourth quarter of 2025, with first patient dosing expected before year-end. Subsequent funding tranches are contingent upon the achievement of key development milestones, including trial patient enrollment.